Prelude Therapeutics has announced new preclinical data on its first-in-class SMARCA2 degrader, PRT3789, and its selective KAT6A degraders at the AACR Annual Meeting. PRT3789 shows potential as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results